Table 1

UKPDS and framingham risk equations
Equations Formula for t-year CHD risk
UKPDS Incident Stevens et al. [3] <a onClick="popup('http://www.biomedcentral.com/1472-6823/12/12/mathml/M1','MathML',630,470);return false;" target="_blank" href="http://www.biomedcentral.com/1472-6823/12/12/mathml/M1">View MathML</a>where d = 1.078 and logeq = −4.4918+ 0.0573× (age-55)0.6444× female-0.9416× Afro-Caribbean + 0.3001× smoking + 0.1681× (HbA1c-6.72) +0.0843× (SPB-135.7)/10 + 1.3468× {loge(TCa/HDL)-1.59}.
UKPDS Duration <a onClick="popup('http://www.biomedcentral.com/1472-6823/12/12/mathml/M2','MathML',630,470);return false;" target="_blank" href="http://www.biomedcentral.com/1472-6823/12/12/mathml/M2">View MathML</a>where T = diabetes duration in years, and d and q were defined as above.

Framingham-Initial

Table 6 in Wilson et al. [4]

Male <a onClick="popup('http://www.biomedcentral.com/1472-6823/12/12/mathml/M3','MathML',630,470);return false;" target="_blank" href="http://www.biomedcentral.com/1472-6823/12/12/mathml/M3">View MathML</a>where m = 0.0483×Age-0.6595× (TCa< 160 mg/dL) + 0.1769×(TC 200-239 mg/dL) + 0.5054×(TC 240-279 mg/dL) + 0.6571×(TC> = 280 mg/dL) + 0.4974×(HDL < 35 mg/dL) + 0.2431× (HDL 35-44 mg/dL)-0.0511× (HDL 50-59 mg/dL)-0.4866× (HDL > =60 mg/dL)-0.0023×(BP Optimal) + 0.2832× (BP High-normal) + 0.5217×(BP Stage-I-hypertension) + 0.6186×(BP Stage-II-IV-hypertension) + 0.4284×Diabetes + 0.5234× (Smoker)-3.0975
S0(1)b=0.9946, S0(2) = 0.9850, S0(3) = 0.9770, S0(4) = 0.9622, S0(5) = 0.95592.
Female <a onClick="popup('http://www.biomedcentral.com/1472-6823/12/12/mathml/M4','MathML',630,470);return false;" target="_blank" href="http://www.biomedcentral.com/1472-6823/12/12/mathml/M4">View MathML</a>where m = 0.3377×Age-0.0027×age2-0.2614×(TCa< 160 mg/dL) + 0.2077×(TC 200-239 mg/dL)+0.2439×(TC 240-279 mg/dL) + 0.5351×(TC > =280 mg/dL)+0.8431×(HDL < 35 mg/dL) + 0.3780×(HDL 35-44 mg/dL)+0.1979×(HDL 45-49 mg/dL)-0.4295×(HDL > =60 mg/dL)0.5336×(BP Optimal)-0.0677×(BP High-normal)+0.2629×(BP Stage-I-hypertension) + 0.4657×(BPStage-II-IV-hypertension) + 0.5963×Diabetes + 0.2925×(Smoker)-9.9255
S0(1)b=0.9984, S0(2) = 0.9933, S0(3) = 0.9909, S0(4) = 0.9858, S0(5) = 0.98297.
Framingham-Secondary Male <a onClick="popup('http://www.biomedcentral.com/1472-6823/12/12/mathml/M5','MathML',630,470);return false;" target="_blank" href="http://www.biomedcentral.com/1472-6823/12/12/mathml/M5">View MathML</a>where m = 4.995–0.0145×age–0.6738× loge(TCa/HDL)-0.3042×Diabetes.
D’Agostino et al. [27]
Female <a onClick="popup('http://www.biomedcentral.com/1472-6823/12/12/mathml/M6','MathML',630,470);return false;" target="_blank" href="http://www.biomedcentral.com/1472-6823/12/12/mathml/M6">View MathML</a>where m = 13.537-0.0225×age0.834×loge(TCa/HDL)-1.3713×ln(SBP)-0.7829×Diabetes-0.3669×smoker.

aTC = Total Cholesterol.

bS0(t) represents the estimate of the t-year baseline survival rate, provided by Framingham investigators, for t = 1,2,…,5 years.

Lu et al.

Lu et al. BMC Endocrine Disorders 2012 12:12   doi:10.1186/1472-6823-12-12

Open Data